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Abstract  
Purpose: To investigate the use of extra-orally applied near infra-red (NIR) 
phototherapy for the reduction of oral pain secondary to chemo-and 
radiation-therapy induced mucositis in adult and pediatric hematopoietic stem 
cell transplant (HSCT) patients.  
Methods: 80 HSCT were divided into regular (R) and low (L) risk groups, 
then to experimental (E) and placebo (P) groups, resulting in 4 groups (ER, 
EL, PR, PL). Experimental subjects received (670 (+/- 10) nm gallium-
aluminum-arsinide light emitting diode (LED) device for 80 sec at an 
~50mW/cm2 energy density and power exposure of 4J/cm2. Placebo patients 
received the same procedures, but with a placebo phototherapy (identical 
device but < 5mW/cm2 energy density). Patients received their respective 
light therapy once per day starting on the day of the HSCT (Day 0) and 
continued through Day +14. Blinded evaluators examined the patients 3 
times per week and scored their oral tissues and patient-reported pain 
assessments at each evaluation utilizing the WHO, NCI-CTCAE, and OMAS 
scales.  
Results: Analysis of the mean scores at each observation demonstrate that 
the extra-oral application of phototherapy resulted in a significant reduction in 
patient-reported pain between the ER and PR patients (P<0.05) at Day +14 
when graded via the WHO criteria. The ER and EL patients were improved in 
almost all other categories and assessment scales, but the differences were 
not statistically significant.  
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Conclusion: Phototherapy demonstrated a significant reduction in patient-
reported pain as measured by the WHO criteria in this patient population. 
Improvement trends were noted in most other assessment measurements.  
 
Keywords: Mucositis, low level laser therapy, photobiomodulation, light 
therapy, pain control  
 
Introduction  
 
Hematopoietic stem cell transplant (HSCT) therapy has 
progressed tremendously since the first transplant was attempted in 
1939. [1] HSCT has become a standard of care for many diseases, and 
in some cases, the first choice therapy rather than being a treatment 
of last resort. [2] Complications suffered by these patients have been 
minimized by advances in infection control and pain management. 
However, mucositis throughout the gastrointestinal tract continues to 
be an extremely difficult complication to manage. [3] Infections in 
ulcerated tissues are life threatening and require aggressive antibiotic 
therapy. Severe mucositis compromises the patient’s ability to take 
oral medications by mouth, causes significant pain, and interferes with 
speech. [4] This can have enormous consequences in very young 
children, who sometimes experience developmental regression and 
long-standing feeding problems following HSCT. Due to inability to 
obtain appropriate nutrition by mouth, parenteral feeding may be 
required but cannot fully replace the nutritional value of a healthy oral 
diet. Furthermore, it may contribute to liver dysfunction, increasing 
morbidity and ultimately the overall success of therapy. [5] Currently, 
Kepivance (Palifermin, KGF Amgen Inc.) has been approved by the 
FDA for prevention of mucositis in a subpopulation of HSCT patients.  
 
Effective treatment or preventive regimen of oral mucositis (OM) 
would be a great advancement in HSCT. Severe OM can lead to 
reduction in the dosage and/or schedule of chemotherapy, which can 
ultimately reduce the efficacy of treatment. Many potential therapies 
have been proposed including granulocyte-macrophage colony 
stimulating factor (GM-CSF) [6], epidermal growth factor [7], 
keratinocyte growth factor [8], interleukin-11 [9], transforming growth 
factor-beta 3 [10], whey growth factor extract-A [11], ice 
(cryotherapy) [12], benzydamine [13], and low-power laser light 
therapy [14-16]. Whelan et al. demonstrated that near infra-red light 
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generated by light emitting diodes (LED’s) at a 670 nm wavelength is 
also capable of reducing the severity and duration of OM [17]. While 
numerous low-power laser treatment reports indicate that patients 
tolerated the intra-oral application of the light therapy, this method of 
delivery requires adequate cooperation on the patient’s part, which can 
be difficult to achieve in children. An effective extra-oral approach to 
this therapy may potentially allow the therapy to be delivered with 
minimal discomfort and improved patient cooperation.  
 
The specific aim of this study was to demonstrate the 
effectiveness of extra-orally applied near-infra-red light (670nm) 
generated by light emitting diodes at reducing the severity of OM pain 
in adult and pediatric patients undergoing myoablative therapy prior to 
HSCT rescue. It is difficult to predict the development and severity of 
oral OM in an individual patient, therefore, the patients in this study 
will be dichotomized into regular or low risk groups depending on their 
HSCT preparation. All patients undergoing myeloablative therapy are 
at risk of developing OM, but there are populations of patients that are 
statistically more likely to develop significant lesions. Allogeneic stem 
cell transplant (SCT) patients have a higher risk of OM than autologous 
SCT patients (18), combined chemoradiation regimens result in higher 
OM rates than chemotherapy alone (19), and multiple drug 
chemotherapy regimens produce more OM than single drug regimens. 
(20)  
 
Methods and Materials  
 
This was a randomized, double-blind, placebo-controlled study 
involving consecutively recruited patients who were undergoing 
myeloablative therapy followed by autologous, matched related, or 
matched, unrelated donor HSCT rescue. The patients were randomized 
to either the control group (sham light treatment) or the experimental 
group (near-infrared LED light treatment).  
 
Recruitment and Randomization  
 
Prospective participants at the Children’s Hospital of Wisconsin 
(CHW), Milwaukee, Wisconsin, the University of Alabama-Birmingham 
(UAB) and The Children’s Hospital of Alabama (TCHA), Birmingham, 
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Alabama were identified at each institution through their respective 
Oncology services. Inclusion criteria included a minimum age of 3 
years and sufficient cooperation to accept the treatment and 
evaluation periods. Prospective patients were excluded from the study 
if they were not expected to be able or willing to cooperate with the 
treatment and evaluation periods. Appropriate consent/assent/parental 
permission was obtained from all patients as approved by the 
Institutional Review Boards of CHW, UAB, and TCHA. All personnel 
involved with the delivery of the treatment and assessments were 
trained in the methodology and reporting standards.  
 
After consent was obtained, the disease diagnosis and 
therapeutic regimen determined whether the patient was deemed a 
regular OM risk group patient or a low OM risk group patient. Patients 
deemed at regular risk included patients receiving total body 
irradiation and an autologous or matched related donor (MRD), a 
matched unrelated donor (MUD), or cord blood transplants; patients 
receiving high dose chemotherapy and autologous stem cell rescue for 
high risk neuroblastoma (carboplatin, etoposide, and 
cyclophosphamide or thiotepa based protocols); patients receiving 
busulfan/cyclophosphamide or busulfan/ cyclophosphamide/etoposide 
and a MRD, MUD, or cord blood transplant for both malignant disease 
and/or non-malignant blood or immune disorder. Patients deemed low 
risk included patients undergoing transplantation for multiple myeloma 
treated with melphalan. Although melphalan is associated with OM, 
this single drug regimen warranted the determination of low OM risk. 
Patients considered high risk mucositis were excluded from enrollment 
and treated with Kepivance.  
 
Consecutive patients were entered into a pre-developed block 
randomization schedule. (Figure 1) Four separate groups were 
evaluated; an experimental/regular risk group (ER), a placebo/regular 
risk group (PR), an experimental/low risk group (EL) and a 
placebo/low risk group (PL). If any patient was dropped from the 
study, the next patient enrolled was substituted. Only persons 
responsible for registering consented patients at participating sites had 
access to this randomization schedule via a secure website and 
updated it accordingly. Investigators were kept blinded.  
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Fig. 1 Flowchart demonstrating recruitment and randomization of 
patients  
 
Daily, experimental subjects were exposed to light emitted from 
an LED device (Warp 75, Quantum Devices, Barneveld, WI) at a 
wavelength of 670 (+/- 10) nm with a power density of ~50 mW/cm2 
for eighty (80) seconds, resulting in an energy delivery of 4 J/cm2 to 
the extra-oral bilateral cheeks and anterior throat tissues; total patient 
dose was 12 J/cm2 /treatment. The light was held in contact or within 
2cm of the extra-oral epithelium of the cheeks and throat. For 
infection control purposes, a clear plastic film (Allrap, Pinnacle/Dental 
Disposables International/TotalCare, Marlboro, MA) covered the device 
and it was cleaned with a hospital-approved disinfectant between 
patients. Control subjects received a sham treatment with the device, 
with the power reduced to 5 mW/cm2. This light intensity 
demonstrated no measurable cellular effects in tissue culture studies. 
[21] All subjects received individual cloth eye masks to maintain 
blinding and to minimize any theoretical risk of eye injury.  
 
Subjects received daily treatment from Day 0 (day of the 
transplant) through Day +14. This endpoint was selected to reduce the 
potential influence of graft-versus-host mucosal changes. Patients 
were assessed at baseline and then thrice weekly (Mon, Wed, Fri). 
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These examinations were performed by trained evaluators. Data on 
pain and oral examinations were recorded according to World Health 
Organization (WHO) cancer therapy standards [22] and the National 
Cancer Institute Common Terminology GI Criteria for Adverse Events 
(NCI). [23] The Oral Mucositis Assessment scale (OMAS) described by 
Sonis [24] was utilized for descriptive purposes. The post-transplant 
day on which each evaluation was completed depended on the day of 
the week the transplant was provided. All patients received the 
baseline evaluation (Evaluation 1) on Day 0. Subsequent evaluations 
were provided on Days +1- +3 (Evaluation 2), Day +3-+5 (Evaluation 
3), Day +5- +7 (Evaluation 4), Day +8- +10 (Evaluation 5), Day +10- 
+12 (Evaluation 6) and Day +12- +14 (Evaluation 7).  
 
Subjective information was received from a patient-completed 
diary form. This form included questions concerning mouth pain and 
was accompanied with a visual analog scale (VAS), with anchors of “no 
pain” and “most severe pain possible”. For pediatric patients, a Wong-
Baker FACES (FACES) pain scale [25] was included for their reporting 
of pain. These two scales were also used by the patient to report the 
impact on swallowing, with the anchors “no trouble” and “unable to 
swallow anything (including saliva)”. The patients also reported 
whether they could eat normally; eat only soft, solid foods; consume 
only liquids; or could not tolerate any food or liquids.  
 
Outcome Measures  
 
The primary outcome measure for analysis was the change in 
scores from baseline on the WHO Pain Assessment scale for OM, 
documented at each evaluation. Secondary outcome measures also 
analyzed were incidence of erythema and ulceration of oral tissues, 
and the duration of erythema and ulcerated tissues. All evaluators 
received training on the appearance of OM lesions and calibration on 
scoring the lesions in the OMAS scale.  
 
Sample size and statistics  
 
The study was powered for the primary comparisons between 
the experimental and control groups based on 5% alpha and 80% 
power. Based on a two-group independent design, the sample size was 
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based on detecting a 25% decrease in the mean pain score between 
the two groups. Due to the large variation in pain perception between 
individuals, the standard deviation is assumed to be no larger than 
39%. With the above mentioned alpha and power, the sample size is 
estimated to be approximately 40 patients per group, for a total of 80 
patients. Chi-square tests were utilized to statistically compare the 
outcomes between the two groups. P values less than 0.05 were 
considered significant.  
 
Blinding  
 
All personnel directly involved with the delivery the 
phototherapy and evaluation of the patients were blinded as to the 
treatment arm. The devices constructed to deliver the light included a 
switch that allowed the device to deliver both the sham and 
experimental treatments. The personnel (trained nurses) delivering 
the phototherapy did not know which switch position was the 
experimental or placebo power density. The patients did not know to 
which treatment arm they were allocated and wore black cloth eye 
shields which prevented them from seeing the switch position on the 
light. Finally, the evaluators did not know to which treatment arm the 
patients had been allocated.  
 
Results  
 
Between March 2007 and April 2009, 85 patients meeting the 
inclusion criteria were consecutively recruited and evaluated from the 
Oncology services of CHW (22 patients), UAB (54 patients), and TCHA 
(11 patients). Five patients were withdrawn; 4 for admittance into an 
intensive care unit due to medical complications not associated with 
the light therapy and 1 voluntarily withdrew because of lack of 
perceived benefit.  
 
Of the final 80 patients, there were 44 males (55%) and 36 
females (45%). The mean age of the patients was 37 years, with a 
range from 3 to 74. The sex and age distribution of the patients in 
each grouping are summarized in Table 1 and the medical diagnosis 
and treatment regimen are listed in Table 2. There was a statistically 
significant difference in the ages only between the regular risk and low 
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risk groups (p<0.0001), but no difference in sex or within the 
experimental or placebo groups. Note that the age difference in the 
low risk group was expected as the low risk group was confined to 
patients receiving single agent melphalan for the treatment of 
myeloma, a disease seen almost exclusively in adults.  
 
 
Table 1 Patient age and sex distribution among treatment groups  
 
 
Table 2 Patient diagnosis and treatment regimen by group assignment 
 
WHO Scales  
 
An exact Mantel-Haenszel Chi-square test was used to compare 
ordered assessment scale differences. There was a significant overall 
difference (Mantel-Haenszel trend test) in the WHO pain assessment 
scale (p=0.0280). Among all patients, there was a significant 
difference between Regular/Low risk groups. (p=0.0226), with the low 
risk groups exhibiting less pain. Within the low risk patients (EL vs PL), 
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there was no significant treatment difference (p=1.0). Within the 
regular risk patients (ER vs PR), there was a significant treatment 
difference (p=0.0422) with the experimental phototherapy group 
exhibiting less pain (44% reduction in mean scores) at the end of the 
study period. (Figure 2) There were no significant differences in the 
WHO clinical examination scale between any of the groups.  
 
 
Fig. 2 Mean differences in WHO pain scores from baseline at each 
evaluation period  
 
Other Assessment Scales  
 
There were no significant differences in the NCI scales for 
clinical examination or function/symptomatic upper GI scores; the 
OMAS erythema or ulceration scale; the VAS or FACES scale; or the 
diet scale between any of the groups. (p>0.05). These results are 
listed in Table 3. Although not statistically significant, many of the data 
suggested a trend for the experimental groups to have general 
improvements in all of these scales, but not the placebo groups. (Table 
4) 
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Discussion 
Pain from cancer therapy related OM can be a debilitating side 
effect that adversely affects the quality of life of these patients. Pain 
can result in a decrease in oral nutritional intake which decreases the 
overall health of the patient. Discovering methods to control this side 
effect while decreasing the need for analgesics would be a tremendous 
advancement in the treatment of cancer patients. 
The reduction in pain scores in this study are consistent with 
other phototherapy studies specifically reporting on OM pain reduction 
[14, 16, 26-31], but differed from Wong et al. who reported no 
significant difference in pain scores [32]. The fundamental difference 
in this study from the previous published reports involves the 
application of the light therapy to the extra-oral tissues rather than an 
intra-oral application. This extra oral application with an LED device 
with a 75cm2 area allowed for the treatment of a large surface area, 
reducing the time to apply the therapy to less than 5 minutes per 
patient per treatment. The above cited reference articles reported 
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treatment times from as low as 5 minutes [28] to as long as 30 
minutes [27] per patient per treatment. 
Extra-oral application of light has the potential advantages of 
delivery of therapy with less invasiveness, reducing the therapy time 
by application of the light over a large surface area at once, and less 
manipulation of potentially painful tissue when placing the light probes 
intra-orally. Conversely, the disadvantage of extra-orally applied light 
therapy involves the diminution of the dose applied to deeper target 
tissues due to absorption, reflection, and refraction of the light by the 
surface tissues. A study by Stolik et al. measured the optical 
penetration depths of different wavelengths through different tissues 
and found that longer wavelengths penetrated deeper into various 
tissues and that the penetration depths varies between 0.2 - 4.01 mm 
for 632.8 nm (HeNe laser) to 0.51 – 4.23 mm for 835 nm light. [33] 
Enwemeka demonstrated that light attenuation occurs most rapidly in 
muscle tissue and that skin does not significantly affect this 
attenuation [34] and that this minimal beam scattering should enable 
sub-dermal lesion treatments. Our own preliminary data on light 
penetration of the human cheek measured a 85.5% reduction in the 
power of our LED light device when measured 2 cm from the light 
source (the approximate distance the light was held off the cheek 
surface in the protocol) to the interior mucosal surface of the cheek 
(21.76 + 2.31 mW/cm2 vs. 3.16 + 0.41 mW/cm2) (unpublished data). 
At this power density (3.16 + 0.41 mW/cm2), it is estimated we 
delivered 0.56 J/cm2 to the mucosal surface. This fluence is slightly 
more than one-half of the fluence reported by Corti et al., which is the 
lowest published fluence to demonstrate a positive effect on OM [35] 
and is slightly less than the fluence delivered by Wong et al. who 
demonstrated no improvement in OM. [32] 
Another difference in our study from others is the use of light 
emitting diodes. Only one other study utilized light emitting diodes 
[29], whereas all others utilized a laser. Some investigators have 
advocated that coherent light such as that found in laser generated 
light therapy is more effective than non-coherent light generated by 
light emitting diodes [36]. Karu [21] has stated that the coherence of 
the light is not a critical determinant in its biologic effect, and 
Enwemeka has further concluded that there is no scientific evidence 
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that supports the theoretical advantages that coherent light may have 
over non-coherent light. [36] 
Another important question that remains to be clearly elucidated 
is the mechanism of action by which phototherapy can provide pain 
relief. Enwemeka et al. reviewed nine pain control studies and 
concluded that these studies had an overall positive effect on pain 
control with phototherapy [37] and possible mechanisms of action 
were identified. A recent review by Bjordal et al. concluded that there 
is strong evidence that low level laser therapy (LLLT) modulates the 
inflammatory process and relieves acute pain in the short term and 
reviewed some of the potential mechanisms of action. [38] These 
included neurophysiologic effects, release of endogenous opioids, local 
microcirculatory and angiogenic effects, local anti-inflammatory 
effects, biochemical marker effects, and cell and soft tissue effects. 
They found a number of controlled laboratory trials that documented 
reductions in the levels of PGE2, TNF, interleukin 1, COX-2 expression, 
and plasminogen activator, as well as cellular and soft tissue studies 
documenting reductions in edema formation, hemorrhagic formation, 
neutrophil cell influx, cell apoptosis, and improvements in 
microcirculation. Cyclooxygenase-2 is one of the enzymes that convert 
arachidonic acid into PGE2, and PGE2 does not by itself cause pain, but 
results in a hyperalgesia state which does induce increased pain 
perception. [39] Sonis et al. demonstrated in a hamster model that 
COX-2 expression paralleled mucositis severity and although it was not 
a primary cause of radiation injury, it did play an amplifying role.[40] 
Stimulation of epithelial cells, fibroblasts and chondrocytes with 
interleukin 1 and tumor necrosis factor-α (TNF-α) results in increased 
PGE2 production as well.[41] Mizutani et al. demonstrated a reduction 
in serum PGE2 levels after phototherapy with an 830 nm GaAlAr laser 
at 1 W.[42] Light therapy may cause a number of small reductions in 
the amplification phase of these cytokines during the mucositis 
process, thereby reducing the hyperalgesia and pain perception. 
This study also failed to show any significant decrease in the 
other measures of OM utilized, which is contrary to multiple published 
reports. [14-17, 26-31, 35, 43, 44] This may be due to the reduction 
of effect of the light caused by the absorption of the power by more 
superficial non-target tissues resulting in inadequate light dosing of the 
target tissues. Given that the estimated fluence delivered to the 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Supportive Care in Cancer, Vol. 20, No. 7 (July 2012): pg. 1405-1415. DOI. This article is © Springer and permission has 
been granted for this version to appear in e-Publications@Marquette. Springer does not grant permission for this article 
to be further copied/distributed or hosted elsewhere without the express permission from Springer. 
15 
 
mucosal surface from the extra-orally applied phototherapy was only 
0.56 J/cm2, this appears to be a reasonable critique. However, the 
review by Bjordal et al. states that light therapy can effectively radiate 
tissue that lies within 10-15mm of the source [38], but these studies 
were of osteoarthritic and other musculoskeletal pain disorders and not 
mucositis. 
Another reason for the lack of improvement in OM parameters 
may be associated with the timing of the phototherapy. In this study, 
the phototherapy was started on Day 0 of the transplant regimen. 
Several other OM studies [14-16, 26-29, 32, 43, 44] started the 
phototherapy prior to or with the start of the myeloablation regimen, 
usually occurring 2-7 days prior to the transplant, whereas others [17, 
30] delivered the phototherapy on or after the day of the transplant or 
appearance of the OM. If the injury to the mucosa occurs with the 
initiation of the myeloablative therapy, and if phototherapy works by 
reducing the amplification of the inflammatory process, starting the 
phototherapy at the initial administration of the myeloablative therapy 
may have resulted in more favorable OM results. 
The low risk patients were statistically significantly older than 
the regular risk patients, and this group did not have any significant 
differences in their incidence of OM or pain reporting. There may be 
several explanations for these phenomena. Firstly, by definition, the 
degree of mucosal injury from a single drug, melphalan, placed these 
patients in this low risk group. [20] The multiple drug interactions in 
the regular risk group can cause significantly more tissue damage and 
produce greater amounts cytokines. Since the low risk patients most 
likely had lower levels of these pro-inflammatory cytokines, the 
proposed interruption in cell signal amplification caused by 
photobiomodulation would not have as great an effect. Another 
potential explanation is the decreased mitochondrial activities and 
increased damaged to mitochondrial DNA associated with human aging 
may have resulted in less photobiostimulatory effects of the 
mitochondria in this older population. [45] Further research is needed 
to elucidate the effects of photobiostimulation on an aging population. 
The extra-oral application of LED phototherapy in this study was 
shown to have a statistically significant reduction in pain as reported 
by the WHO Pain Assessment scale for OM, but not for other mucositis 
scoring scales such as the NCI and OMAS scales. Much further 
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research is needed through controlled trials to establish the 
appropriate timing, dose, power, and fluence of the phototherapy to 
determine the optimum therapeutic parameters. 
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